# Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL

> **NCT02848911** · PHASE1 · TERMINATED · sponsor: **Affimed GmbH** · enrollment: 17 (actual)

## Conditions studied

- Leukemia, B-Cell

## Interventions

- **DRUG:** AFM11

## Key facts

- **NCT ID:** NCT02848911
- **Lead sponsor:** Affimed GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10
- **Primary completion:** 2018-09
- **Final completion:** 2019-04
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Strategic decision was made to terminate the AFM11 development
- **Last updated:** 2019-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02848911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02848911, "Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02848911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*